Mckesson Corp(MCK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 5:36 PM ET (Korea 9/11 06:36)
Full metrics table
| Index | S&P 500 | P/E | 23.57 | EPS (ttm) | 37.37 | Insider Own | 0.07% | Shs Outstand | 116.6M | Perf Week | -4.75% |
| Market Cap | 102.70B | Forward P/E | 17.42 | EPS next Y | 13.27% | Insider Trans | -27.51% | Shs Float | 116.5M | Perf Month | -2.32% |
| Enterprise Value | 112.08B | PEG | 1.25 | EPS next Q | 10.72 | Inst Own | 94.44% | Short Float | 2.08% | Perf Quarter | 11.44% |
| Income | 4.59B | P/S | 0.25 | EPS this Y | 14.11% | Inst Trans | -2.9% | Short Ratio | 2.35 | Perf Half Y | -5.72% |
| Sales | 410.98B | P/B | - | EPS next 5Y | 13.89% | ROA | 5.41% | Short Interest | 2.42M | Perf YTD | 7.38% |
| Book/sh | -36.55 | P/C | 19.54 | EPS past 3/5Y | 15.3% - | ROE | - | 52W High | -11.83% ($999.00) | Perf Year | 24.72% |
| Cash/sh | 45.08 | P/FCF | 16.01 | Sales past 3/5Y | 13.39% 11.11% | ROIC | 78.2% | 52W Low | 28.09% ($687.68) | Perf 3Y | 109.34% |
| Dividend Est. | $3.27 (0.37%) | EV/EBITDA | 14.98 | EPS Y/Y TTM | 48.98% | Gross Margin | 3.43% | Volatility(W/M) | 2.05% 2.38% | Perf 5Y | 334.5% |
| Dividend TTM | 3.4 | EV/Sales | 0.27 | Sales Y/Y TTM | 8.84% | Oper. Margin | 1.63% | ATR (14) | 23.1 | Perf 10Y | 400.23% |
| Dividend Ex-Date | 2026/9/1 | Quick Ratio | 0.52 | EPS Q/Q | -17.54% | Profit Margin | 1.12% | RSI (14) | 50.43 | Recom | 1.68 |
| Dividend Gr. 3/5Y | 14.9% 13.68% | Current Ratio | 0.89 | Sales Q/Q | 7.72% | SMA20 | -0.32% ($883.69) | Beta | 0.29 | Target Price | $988.19 |
| Payout | 8.26% | Debt/Eq | - | Earnings | 2026/8/5 | SMA50 | 3.01% ($855.12) | Rel Volume | 0.77 | Prev Close | $891.68 |
| Employees | 43000 | LT Debt/Eq | - | EPS/Sales Surpr. | 3.86% 1.45% | SMA200 | 4.4% ($843.74) | Avg Volume(3M) | 1.03M | Price | $880.86 |
| IPO | 1994/11/10 | Option/Short | Yes/Yes | Trades | 21624 | Volume | 793,335 | Change | -1.21% |
Company
MCK is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 This is one of the "Big Three" U.S. pharmaceutical distributors and a comprehensive healthcare company that provides global pharmaceutical distribution and medical solutions. Founded in 1833 and headquartered in the U.S., it has established itself as a core player in the U.S. prescription drug distribution market.
Over the past 1 year, roughly in the middle
12% below its 1-year high.
MCK has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +14.1% this year.
Tap to view numbers
The price looks about right
Trading at 23.6 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +109.3% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 0.37% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 94.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SEMG 0.05%
FCTE 0.05%
USSE 0.05%
RTH 0.04%
WCEO 0.04%It is the largest in the industry
Based on market cap of $103B.
MCK $103B PER 23.6
COR $61B PER 23.9
CAH $55B PER 32.6
HSIC $10B PER 25.4
FAQ
What kind of company is MCK?
MCK belongs to the Healthcare sector and operates in the Medical Distribution industry.
What is the market cap of MCK?
The market cap of MCK is approximately $102.7B, ranking 159 within its sector.
Does MCK pay dividends?
MCK has a dividend yield of approximately 0.37%, with an annual dividend of $3.27.
What is the P/E ratio of MCK?
MCK has a P/E ratio of approximately 23.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for MCK?
MCK has recorded a 52-week high of $999.00 and a low of $687.68.
